LSI Medience Corporation provides medical and analytical support services across Japan and is one of the leading providers of clinical testing services. The company’s high quality solutions contribute to the prevention, early detection and effective treatment of illnesses. Its three core businesses are clinical testing, In Vitro Diagnostics products and reagents, and drug development support.
As one of Japan’s top three companies in the clinical testing business, their lab automation system responds to clinical testing needs to enable speed and precision. They deliver various services for medical institutions from an electronic medical record system to clinical testing service across a wide testing portfolio that includes: biochemistry, hematology, immunology, microbiology and genetics.
With an extensive equipment line-up of clinical diagnostic reagents and instruments, LSI Medience responds to the needs of customers, enabling them to perform highly accurate and quick tests. One of these products, the PATHFAST™ analysis system, combines the accuracy of a full-scale lab with the flexibility of a mobile solution.
LSI Medience was acquired by PHC Holdings in 2019 from LSI Institute. The company aims to create a healthy and safe society using the power of medical science. They also support research and analysis for drug development, sports doping tests and COVID-19 testing.